Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for Which There Is No Treatment

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2016 Jun 1

PMID 27242702

Citations 4

Authors

Jose Mengel

Fabiola Cardillo

Lain Pontes-de-Carvalho

Affiliations

Soon will be listed here.

Citing Articles

The Blockade of Interleukin-2 During the Acute Phase of Infection Reveals Its Dominant Regulatory Role.

Nihei J, Cardillo F, Mengel J Front Cell Infect Microbiol. 2021; 11:758273.

PMID: 34869064 PMC: 8635756. DOI: 10.3389/fcimb.2021.758273.

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy.

Farani P, Begum K, Vilar-Pereira G, Resende Pereira I, Almeida I, Roy S Front Cell Infect Microbiol. 2021; 11:692655.

PMID: 34381739 PMC: 8351877. DOI: 10.3389/fcimb.2021.692655.

Regulatory Lymphoid and Myeloid Cells Determine the Cardiac Immunopathogenesis of Infection.

Fresno M, Girones N Front Microbiol. 2018; 9:351.

PMID: 29545782 PMC: 5838393. DOI: 10.3389/fmicb.2018.00351.

Effects of dexmedetomidine on TNF-α and interleukin-2 in serum of rats with severe craniocerebral injury.

Jiang W, Wang Q, Liao Y, Peng P, Xu M, Yin L BMC Anesthesiol. 2017; 17(1):130.

PMID: 28931374 PMC: 5607498. DOI: 10.1186/s12871-017-0410-7.

References

Lee B, Bacon K, Bottazzi M, Hotez P . Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013; 13(4):342-8. PMC: 3763184. DOI: 10.1016/S1473-3099(13)70002-1. View

Campen D, Horwitz D, Quismorio Jr F, Ehresmann G, Martin W . Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988; 31(11):1358-64. DOI: 10.1002/art.1780311103. View

Roffe E, Rothfuchs A, Santiago H, Marino A, Ribeiro-Gomes F, Eckhaus M . IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of Trypanosoma cruzi infection. J Immunol. 2011; 188(2):649-60. PMC: 3253255. DOI: 10.4049/jimmunol.1003845. View

Stockinger B, Kassiotis G, Bourgeois C . Homeostasis and T cell regulation. Curr Opin Immunol. 2004; 16(6):775-9. DOI: 10.1016/j.coi.2004.09.003. View

Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner V . Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet. 2007; 39(3):329-37. PMC: 2886969. DOI: 10.1038/ng1958. View

Maguire J . Treatment of Chagas' Disease--Time Is Running Out. N Engl J Med. 2015; 373(14):1369-70. DOI: 10.1056/NEJMe1510170. View

Liao W, Lin J, Leonard W . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013; 38(1):13-25. PMC: 3610532. DOI: 10.1016/j.immuni.2013.01.004. View

Oft M . IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014; 2(3):194-9. DOI: 10.1158/2326-6066.CIR-13-0214. View

Briceno L, Mosca W . Defective production of interleukin 2 in patients with Chagas' disease. Purified IL-2 augments in vitro response in patients with chagasic cardiomyopathy. Mem Inst Oswaldo Cruz. 1996; 91(5):601-7. DOI: 10.1590/s0074-02761996000500011. View

10.

Vieira Q, Kayser C, Kallas E, Andrade L . Decreased recent thymus emigrant number is associated with disease activity in systemic lupus erythematosus. J Rheumatol. 2008; 35(9):1762-7. View

11.

Thewissen M, Linsen L, Somers V, Geusens P, Raus J, Stinissen P . Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients. Ann N Y Acad Sci. 2005; 1051:255-62. DOI: 10.1196/annals.1361.066. View

12.

Rassi Jr A, Rassi A, Marin-Neto J . Chagas disease. Lancet. 2010; 375(9723):1388-402. DOI: 10.1016/S0140-6736(10)60061-X. View

13.

Andrade D, Gollob K, Dutra W . Acute chagas disease: new global challenges for an old neglected disease. PLoS Negl Trop Dis. 2014; 8(7):e3010. PMC: 4117453. DOI: 10.1371/journal.pntd.0003010. View

14.

Laucella S, Riarte A, Prado N, Zapata J, Segura E . alpha 4 Integrins and sialyl Lewis x modulation in chronic Chagas disease: further evidence of persistent immune activation. Scand J Immunol. 2001; 53(5):514-9. DOI: 10.1046/j.1365-3083.2001.00916.x. View

15.

Cardillo F, de Pinho R, Antas P, Mengel J . Immunity and immune modulation in Trypanosoma cruzi infection. Pathog Dis. 2015; 73(9):ftv082. PMC: 4626602. DOI: 10.1093/femspd/ftv082. View

16.

Hunter C, Slifer T, Kanaly S, Grunig G, Fort M, Rennick D . IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol. 1997; 158(7):3311-6. View

17.

Thewissen M, Somers V, Venken K, Linsen L, van Paassen P, Geusens P . Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol. 2007; 123(2):209-18. DOI: 10.1016/j.clim.2007.01.005. View

18.

Humrich J, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A . Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015; 74(4):791-2. DOI: 10.1136/annrheumdis-2014-206506. View

19.

Kosmaczewska A . Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity. Int J Mol Sci. 2014; 15(10):18574-92. PMC: 4227233. DOI: 10.3390/ijms151018574. View

20.

Morillo C, Marin-Neto J, Avezum A, Sosa-Estani S, Rassi Jr A, Rosas F . Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015; 373(14):1295-306. DOI: 10.1056/NEJMoa1507574. View